Amgen’s Rare Disease Drug Tavneos Tied to 20 Deaths in Japan

Why It Matters

The emerging safety signal threatens Tavneos’s market viability and could prompt regulatory actions that impact Amgen’s revenue and reputation in the rare‑disease space.

Key Takeaways

• 20 deaths among 8,500 Tavneos patients in Japan
• Deaths linked to vanishing bile duct syndrome, a liver injury
• FDA flagged 76 VBS cases and eight deaths in U.S. data
• Amgen denies FDA pull request, maintains benefit‑risk claim
• Alleged data manipulation undermines original approval validity

Pulse Analysis

Tavneos, an anti‑complement therapy approved for paroxysmal nocturnal hemoglobinuria, became a flagship asset after Amgen’s $3.7 billion acquisition of ChemoCentryx in 2022. The drug’s promise lies in its ability to reduce hemolysis and transfusion dependence, positioning it as a high‑margin product in the growing rare‑disease portfolio. However, its commercial trajectory now faces headwinds as safety concerns surface in key markets, prompting stakeholders to reassess risk exposure and pricing strategies.

In Japan, an automated safety alert from Kissei Pharmaceutical identified 20 fatalities among roughly 8,500 treated patients, most associated with vanishing bile duct syndrome (VBS), a rare but fatal liver injury. The Japanese partner has issued a precautionary advisory, urging physicians to halt new prescriptions and closely monitor existing users. Across the Pacific, the FDA’s March review documented 76 VBS cases and eight deaths, concluding there is reasonable evidence of a causal link. These parallel signals amplify regulatory pressure and could trigger label revisions, market withdrawals, or litigation, directly affecting Amgen’s earnings forecasts.

Compounding the safety dilemma, the FDA has raised allegations of data manipulation in the pivotal trial that underpinned Tavneos’s original approval. While Amgen disputes the regulator’s request to pull the drug, the accusation erodes confidence in the drug’s efficacy claims and may invite further investigations. For investors and clinicians, the convergence of adverse event reports and integrity concerns underscores the importance of robust pharmacovigilance and transparent data practices. Amgen’s response—maintaining a favorable benefit‑risk narrative while launching an information campaign—will be pivotal in determining whether Tavneos can recover its standing or become a cautionary tale in biotech acquisitions.